Indivior Pharmaceuticals (INDV) EBIAT (2022 - 2025)
Historic EBIAT for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to $42.0 million.
- Indivior Pharmaceuticals' EBIAT rose 9090.91% to $42.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $128.0 million, marking a year-over-year increase of 22000.0%. This contributed to the annual value of $7.0 million for FY2024, which is 10555.56% up from last year.
- As of Q3 2025, Indivior Pharmaceuticals' EBIAT stood at $42.0 million, which was up 9090.91% from $18.0 million recorded in Q2 2025.
- Indivior Pharmaceuticals' 5-year EBIAT high stood at $61.0 million for Q1 2024, and its period low was -$183.0 million during Q4 2022.
- Over the past 4 years, Indivior Pharmaceuticals' median EBIAT value was $40.0 million (recorded in 2022), while the average stood at $1.6 million.
- Examining YoY changes over the last 5 years, Indivior Pharmaceuticals' EBIAT showed a top increase of 12950.82% in 2023 and a maximum decrease of 42926.83% in 2023.
- Indivior Pharmaceuticals' EBIAT (Quarter) stood at -$183.0 million in 2022, then surged by 129.51% to $54.0 million in 2023, then plummeted by 61.11% to $21.0 million in 2024, then surged by 100.0% to $42.0 million in 2025.
- Its EBIAT was $42.0 million in Q3 2025, compared to $18.0 million in Q2 2025 and $47.0 million in Q1 2025.